Pharming plans redundancies to provide €3.5-5m annual cost reductions
This article was originally published in Scrip
Pharming Group has announced a strategic restructuring plan of its Dutch operations that will see in excess of 20 redundancies from its workforce. The plan is designed to accelerate the company's path to sustainability and future profitability, it said, adding that through this move, "the company aims to reduce costs by approximately €3.5-5 million annually over the coming 12-18 months".
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.